Cost Effectiveness of Different Platelet Preparation, Storage, Selection and Dosing Methods in Platelet Transfusion: A Systematic Review.
Journal
PharmacoEconomics - open
ISSN: 2509-4254
Titre abrégé: Pharmacoecon Open
Pays: Switzerland
ID NLM: 101700780
Informations de publication
Date de publication:
Sep 2023
Sep 2023
Historique:
accepted:
24
05
2023
medline:
27
6
2023
pubmed:
27
6
2023
entrez:
26
6
2023
Statut:
ppublish
Résumé
Evidence-based guidelines on platelet transfusion therapy assist clinicians to optimize patient care, but currently do not take into account costs associated with different methods used during the preparation, storage, selection and dosing of platelets for transfusion. This systematic review aimed to summarize the available literature regarding the cost effectiveness (CE) of these methods. Eight databases and registries, as well as 58 grey literature sources, were searched up to 29 October 2021 for full economic evaluations comparing the CE of methods for preparation, storage, selection and dosing of allogeneic platelets intended for transfusion in adults. Incremental CE ratios, expressed as standardized cost (in 2022 EUR) per quality-adjusted life-year (QALY) or per health outcome, were synthesized narratively. Studies were critically appraised using the Philips checklist. Fifteen full economic evaluations were identified. Eight investigated the costs and health consequences (transfusion-related events, bacterial and viral infections or illnesses) of pathogen reduction. The estimated incremental cost per QALY varied widely from EUR 259,614 to EUR 36,688,323. For other methods, such as pathogen testing/culturing, use of apheresis instead of whole blood-derived platelets, and storage in platelet additive solution, evidence was sparse. Overall, the quality and applicability of the included studies was limited. Our findings are of interest to decision makers who consider implementing pathogen reduction. For other preparation, storage, selection and dosing methods in platelet transfusion, CE remains unclear due to insufficient and outdated evaluations. Future high-quality research is needed to expand the evidence base and increase our confidence in the findings.
Sections du résumé
BACKGROUND AND OBJECTIVE
OBJECTIVE
Evidence-based guidelines on platelet transfusion therapy assist clinicians to optimize patient care, but currently do not take into account costs associated with different methods used during the preparation, storage, selection and dosing of platelets for transfusion. This systematic review aimed to summarize the available literature regarding the cost effectiveness (CE) of these methods.
METHODS
METHODS
Eight databases and registries, as well as 58 grey literature sources, were searched up to 29 October 2021 for full economic evaluations comparing the CE of methods for preparation, storage, selection and dosing of allogeneic platelets intended for transfusion in adults. Incremental CE ratios, expressed as standardized cost (in 2022 EUR) per quality-adjusted life-year (QALY) or per health outcome, were synthesized narratively. Studies were critically appraised using the Philips checklist.
RESULTS
RESULTS
Fifteen full economic evaluations were identified. Eight investigated the costs and health consequences (transfusion-related events, bacterial and viral infections or illnesses) of pathogen reduction. The estimated incremental cost per QALY varied widely from EUR 259,614 to EUR 36,688,323. For other methods, such as pathogen testing/culturing, use of apheresis instead of whole blood-derived platelets, and storage in platelet additive solution, evidence was sparse. Overall, the quality and applicability of the included studies was limited.
CONCLUSIONS
CONCLUSIONS
Our findings are of interest to decision makers who consider implementing pathogen reduction. For other preparation, storage, selection and dosing methods in platelet transfusion, CE remains unclear due to insufficient and outdated evaluations. Future high-quality research is needed to expand the evidence base and increase our confidence in the findings.
Identifiants
pubmed: 37365482
doi: 10.1007/s41669-023-00427-w
pii: 10.1007/s41669-023-00427-w
pmc: PMC10471540
doi:
Types de publication
Systematic Review
Langues
eng
Pagination
679-708Subventions
Organisme : European Blood Alliance
ID : 2021-01
Informations de copyright
© 2023. The Author(s).
Références
Transfusion. 1999 Sep;39(9):925-32
pubmed: 10533816
Transfus Med Rev. 2015 Jan;29(1):3-13
pubmed: 25537844
Transfusion. 2010 Oct;50(10):2220-32
pubmed: 20492607
Cochrane Database Syst Rev. 2015 Oct 27;(10):CD010984
pubmed: 26505729
Health Technol Assess. 2004 Sep;8(36):iii-iv, ix-xi, 1-158
pubmed: 15361314
Transfusion. 2018 Jul;58(7):1647-1653
pubmed: 29607515
Transfusion. 2009 Nov;49(11):2442-53
pubmed: 19903296
Transfusion. 2006 Jun;46(6):956-65
pubmed: 16734812
Int J Hematol. 2004 Nov;80(4):317-24
pubmed: 15615255
Transfus Med Rev. 2020 Oct;34(4):250-257
pubmed: 33127210
Vox Sang. 2023 Jan;118(1):16-23
pubmed: 36454598
Transfusion. 2013 Nov;53(11):2609-18
pubmed: 23363552
Transfus Med Hemother. 2015 May;42(3):158-65
pubmed: 26195929
Transfus Med. 2006 Feb;16(1):17-30
pubmed: 16480436
Am J Clin Pathol. 2000 Dec;114(6):934-7
pubmed: 11338483
Cost Eff Resour Alloc. 2003 Dec 19;1(1):8
pubmed: 14687420
Transfusion. 2010 Nov;50(11):2461-73
pubmed: 20497512
Vox Sang. 2017 May;112(4):291-300
pubmed: 28271517
Transfusion. 2003 Jun;43(6):721-9
pubmed: 12757522
Transfus Med. 2005 Oct;15(5):379-87
pubmed: 16202052
Transfusion. 1993 Aug;33(8):665-70
pubmed: 8342234
N Engl J Med. 1995 Mar 16;332(11):719-24
pubmed: 7854380
Br J Haematol. 2017 Feb;176(3):365-394
pubmed: 28009056
Ann Intern Med. 2015 Feb 03;162(3):205-13
pubmed: 25383671
Clin Ther. 2003 Sep;25(9):2464-86
pubmed: 14604745
Value Health. 2021 Apr;24(4):463-472
pubmed: 33840423
Transfus Med Hemother. 2018 Apr;45(2):98-102
pubmed: 29765292
Transfusion. 1986 Jan-Feb;26(1):91-7
pubmed: 3080832
BMJ. 2007 Aug 25;335(7616):358-9
pubmed: 17717337